Aethlon Medical stockholders approve tenfold increase in authorized common stock

Aethlon Medical, Inc. stockholders approved a tenfold increase in the company's authorized common shares during its annual meeting on October 1, 2026. The Nevada-based medical device firm, which trades under the ticker AEMD on the Nasdaq Capital Market, secured approval for an amendment to its Articles of Incorporation that raises the authorized share count from 20,000,000 to 200,000,000. This move provides the board with significantly greater flexibility to issue equity in the future, a change that directly impacts the potential dilution for existing holders of the San Diego company's common stock.

The vote was part of a broader set of proposals presented to shareholders at the virtual annual meeting. As of the record date on August 10, 2026, Aethlon had 711,136 shares of common stock issued and outstanding. Of those shares, 399,752 were represented by proxy or in person, constituting approximately 56.21% of the total and establishing a quorum for the proceedings.

In addition to the capital structure change, shareholders approved several other key measures. The board was authorized to issue up to 1,126,602 shares upon the exercise of warrants issued during a July 2026 offering, a step required to comply with Nasdaq Listing Rule 5635(d). The company also received approval to issue common stock or convertible securities for future private financing transactions and warrant exercise inducements, both under the same Nasdaq compliance provision. Furthermore, stockholders ratified the appointment of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2027.

The annual meeting also saw the election of five directors to serve until the next annual meeting or until their successors are elected. The directors elected were Edward G. Broenniman, James B. Frakes, Nicolas Gikakis, Angela Rossetti, and Chetan S. Shah, MD. Each director received substantial support from shareholders, with votes for their election ranging from over 209,000 to over 211,000 shares. The board also secured approval for an amendment to the 2020 Equity Incentive Plan, increasing the number of shares authorized for issuance under that plan by 100,000.

The company filed a Form 8-K with the Securities and Exchange Commission on October 1, 2026, to report these results. The filing noted that the Plan Amendment became effective upon receipt of stockholder approval. Detailed terms of the amended plan are referenced in the company's Definitive Proxy Statement filed on August 21, 2026. The approval of the expanded authorized share count marks a significant shift in Aethlon Medical's corporate governance and capital planning capabilities.